Scarica l'app Stockscreener
1.32
4.76%
0.06
Dopo l'orario di chiusura:
1.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.26
Aprire:
$1.27
Volume 24 ore:
9.59M
Relative Volume:
1.39
Capitalizzazione di mercato:
$398.64M
Reddito:
$160.01M
Utile/perdita netta:
$-546.38M
Rapporto P/E:
-0.7193
EPS:
-1.835
Flusso di cassa netto:
$-118.92M
1 W Prestazione:
-5.04%
1M Prestazione:
-21.43%
6M Prestazione:
+3.13%
1 anno Prestazione:
+11.86%
Intervallo 1D:
$1.27
$1.338
Intervallo di 1 settimana:
$1.23
$1.45
Portata 52W:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.32 | 380.52M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Pacific Biosciences of California unveils oncology workflow solutions at industry event - Traders Union
Returns Recap: Will Pacific Biosciences of California Inc outperform during market rallies2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Pacific Biosciences Stock: Long-Read Sequencing Leader Faces Evolving Genomics Landscape - AD HOC NEWS
Stock List: Research Stocks from Around the World - GuruFocus
Stock Report: Can Pacific Biosciences of California Inc reach all time highs this year2026 Final Week & Real-Time Stock Movement Alerts - baoquankhu1.vn
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Vanguard amendment shows 0 PACB shares after realignment (PACB) - Stock Titan
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider - Bitget
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - MSN
PacBio Secures Agreement with Basecamp Research for Trillion Gene Atlas Project - Bitget
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Turn Cautious - Yahoo Finance
PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative - Eastern Progress
Panic Selling: Will Pacific Biosciences of California Inc outperform tech stocks2026 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Earnings Update: Should I invest in Pacific Biosciences of California Inc before earnings2026 Weekly Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Pacific Biosciences of California grants early SPRQ-Nx beta access to scientists for HiFi sequencing - Traders Union
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pacific Biosciences of California (PACB) Falls Further Than the Overall Market: Key Information to Note - Bitget
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Pacific Biosciences of California expands cancer research with new epigenetics lesson in sequencing series - Traders Union
DNA Sequencing Market size to hit $108.95 Billion by 2035 | Top - openPR.com
Canaccord reiterates Pacific Biosciences stock rating on new chemistry By Investing.com - Investing.com Canada
Canaccord reiterates Pacific Biosciences stock rating on new chemistry - Investing.com
PacBio (PACB) Collaborates on Groundbreaking Trillion Gene Atlas Project - GuruFocus
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative - marketscreener.com
Inside the trillion-gene atlas training AI to design new medicines - Stock Titan
Pacific Biosciences of California unveils DNA sequencing method boosting accuracy to 99.9 percent - Traders Union
Volume Summary: Does Pacific Biosciences of California Inc have a sustainable dividend2026 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
Pacific Biosciences of California urges last call for webinar on HiFi sequencing advances in cancer research - Traders Union
PacBio and DNAstack collaborate on global HiFi genome network hub - MSN
Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis - Traders Union
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio - geneonline.com
Pacific Biosciences of California technology maps cancer structural variants in single platform advance - Traders Union
PACB,TAL Options - Finviz
PACB,TAL Volatility & Greeks - Finviz
Chart Watch: Will Pacific Biosciences of California Inc outperform during market ralliesWeekly Earnings Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences of California reports prelim Q4, FY revenue above estimate - MSN
Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
Patent deal locks in protections for Pacific Biosciences (NASDAQ: PACB) with PGI - Stock Titan
Pacific Biosciences of California, Inc. Announces Chief Accounting Officer Changes, Effective March 21, 2026 - marketscreener.com
PACB - Finviz
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat
Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada
Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pacific Biosciences Of California Inc Azioni (PACB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
6,504 |
9,847 |
2,243,634 |
| Farmer Michele | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
2,979 |
4,510 |
305,948 |
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):